Stock of The Day: Could Chiasma Inc Change Direction After Today’s Significant Decline?

Stock of The Day: Could Chiasma Inc Change Direction After Today's Significant Decline?

The stock of Chiasma Inc (NASDAQ:CHMA) is a huge mover today! About 76,372 shares traded hands. Chiasma Inc (NASDAQ:CHMA) has declined 69.86% since March 8, 2016 and is downtrending. It has underperformed by 79.18% the S&P500.
The move comes after 8 months negative chart setup for the $70.10 million company. It was reported on Oct, 11 by We have $2.48 PT which if reached, will make NASDAQ:CHMA worth $9.11M less.

Analysts await Chiasma Inc (NASDAQ:CHMA) to report earnings on November, 10. They expect $-0.66 EPS, down 43.48% or $0.20 from last year’s $-0.46 per share. After $-0.83 actual EPS reported by Chiasma Inc for the previous quarter, Wall Street now forecasts -20.48% EPS growth.

Chiasma Inc (NASDAQ:CHMA) Ratings Coverage

Out of 3 analysts covering Chiasma (NASDAQ:CHMA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Chiasma has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Equal-Weight” rating given by Barclays Capital on Monday, April 25. The stock of Chiasma Inc (NASDAQ:CHMA) earned “Overweight” rating by Barclays Capital on Monday, August 10. The firm has “Outperform” rating given on Monday, August 10 by Cowen & Co. As per Monday, August 10, the company rating was initiated by William Blair. The firm has “Market Perform” rating given on Monday, April 18 by William Blair.

According to Zacks Investment Research, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA.”

More notable recent Chiasma Inc (NASDAQ:CHMA) news were published by: which released: “Chiasma’s stock plummets 54% premarket after FDA response letter” on June 18, 2015, also with their article: “Chiasma, Inc. Prices Initial Public Offering of Common Stock” published on July 15, 2015, published: “Chiasma, Inc. (CHMA) Names Mark J. Fitzpatrick as CEO” on September 30, 2016. More interesting news about Chiasma Inc (NASDAQ:CHMA) were released by: and their article: “Chiasma, Inc. (CHMA) Announces Additional 44% Workforce Reduction” published on August 16, 2016 as well as‘s news article titled: “Chiasma Inc. CHMA (US: Nasdaq)” with publication date: July 10, 2015.

CHMA Company Profile

Chiasma, Inc., incorporated on April 12, 2001, is a biopharmaceutical company. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Firm has completed a Phase III clinical trial of its TPE platform product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment